The past two years have been incredible for Moderna (NASDAQ: MRNA) -- and its investors. Positive and negative factors will compete to determine which direction Moderna stock takes in 2022. Let's take a look at one green flag for Moderna in the coming year -- and one red flag.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting